Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | VIR-5525 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on VIR-5525, a putative T-cell engager targeting EGFR (May 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| VIR-5525 | AMX-525|AMX525|AMX 525|VIR 5525|VIR5525 | EGFR Antibody 72 | Limited information is currently available on VIR-5525, a putative T-cell engager targeting EGFR (May 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06960395 | Phase I | Pembrolizumab + VIR-5525 VIR-5525 | Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |